Navigation Links
Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)

SAN DIEGO, April 15 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. today announced a collaboration with Amylin Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam(R) technology platform from Pacira. The companies will work together to enhance the dosing profile for compounds within Amylin's early research and development pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection.

Dave Stack, President and CEO of Pacira stated, "In addition to our own lead development candidate, DepoBupivacaine(TM), we believe that delivery of Amylin's compounds using the DepoFoam(R) technology would create significant value for patient care, our partners, and Pacira."

"Pacira's DepoFoam(R) technology is an attractive delivery system and Amylin is excited to apply this technology to our peptide and protein therapeutics platform," said Christopher Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences of Amylin. "This collaboration fits well with Amylin's research and development activities, which leverage our expertise in metabolism to develop potential therapies for diabetes and obesity."

Terms of the agreement are not disclosed at this time.

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing Products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post- surgical pain. Additional information about Pacira is available at

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
2. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
3. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
4. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
7. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
8. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
9. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Post Your Comments:
(Date:11/23/2015)... VA (PRWEB) , ... November 23, 2015 , ... Noblis, ... McCarthy , former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined ... us with an incredibly distinguished career in the intelligence community and the private sector,” ...
(Date:11/23/2015)... , November 23, 2015 biochar ... million in 2015, and it is expected to grow ... The factors driving the growth of the global market ... sequestration property of biochar, increased government initiatives and stringent ... initiatives and stringent environment regulations are the key drivers ...
(Date:11/23/2015)... Fla. , Nov. 23, 2015  Oxis ... Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: ... of Minnesota Masonic Cancer Center received notification from ... they can proceed with their planned combination Phase ... worldwide exclusive rights to develop and commercialize OXS-1550, ...
(Date:11/23/2015)... 2015 ) ... Global Molecular Diagnostics Market: Latest Instrumentation and ... to their offering.  --> ... "2016 Global Molecular Diagnostics Market: Latest Instrumentation ...  report to their offering.  --> ...
Breaking Biology Technology:
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):